更新于：2024-11-15
Cefprozil
头孢丙烯
更新于：2024-11-15
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H21N3O6S |
InChIKeyALYUMNAHLSSTOU-PFBPGKLMSA-N |
CAS号121123-17-9 |
关联
49
项与 头孢丙烯 相关的临床试验Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
头孢丙烯片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹/餐后状态下生物等效性试验
头孢丙烯片随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
100 项与 头孢丙烯 相关的临床结果
登录后查看更多信息
100 项与 头孢丙烯 相关的转化医学
登录后查看更多信息
100 项与 头孢丙烯 相关的专利（医药）
登录后查看更多信息
335
项与 头孢丙烯 相关的文献（医药）2024-02-01Therapeutic delivery
Aquasomes Nanoformulation for Controlled Release of Drug and Improved Effectiveness Against Bacterial Infections
Article
作者: Shanmugam, Bhuvaneshwari ; Srinivasan, Umashankar Marakanam
Aim: The study aimed to develop and evaluate an aquasome drug-delivery system for controlled drug delivery of cefprozil monohydrate. Materials & methods: Aquasomes were prepared by the spinal method with a calcium phosphate core, sugar-coated using cellobiose and drug-loaded by adsorption. The formulations were characterized for size, morphology and drug release. An antibacterial study was conducted for Gram-positive and -negative bacteria. Results: It showed particle size of 2791.9 nm, zeta potential of -0.3 mV with good stability, and 99.08% of drug loading and drug release were controlled and prolonged, achieving 56% within 8 h and possessing potential for 100% release beyond 12 h. Conclusion: An aquasome drug-delivery system was developed for novel controlled drug delivery for pharmaceutical antibiotic therapeutics.
2024-01-01Medical Bulletin of Sisli Etfal Hospital
Evaluation of Cross-Reactivity Between Penicillins and Cephalosporins in Children with a History of Cephalosporin Allergy
Article
作者: Cetinkaya, Feyzullah ; Kutluk, Gunsel ; Eker, Nursah
Objectives:
The cross-reactivity problem between cephalosporins and penicillins has mainly been evaluated in the context of patients allergic to penicillins. However, we have little data regarding the opposite aspect of the problem, i.e. the cross-reactivity in subjects primarily sensitized to cephalosporins. This prospective study aims to evaluate the cross-reactivity to penicillins and some other cephalosporins in patients with immediate allergic reactions to cephalosporins.
Methods:
The study included 21 children with immediate allergic reactions to at least one cephalosporin. Skin testing was performed with a panel of minor and major determinant mixtures of penicillins and three commonly used cephalosporins (cephazoline, cefuroxime and ceftriaxone).
Results:
The children had used 5.14±4.91 (1-15) times any beta-lactam antibiotic in the previous year and the most common cephalosporins accused were ceftriaxone (42.92%), and cefuroxime, cefazolin, cefixime, cefprozil and cefotaxime (9.5% each). Skin tests were positive for any cephalosporin in 14 (66.7%) subjects and penicillin allergens in 15 (71.4%) subjects. Totally, 85.7% of children with a positive allergy history to cephalosporins were found to be sensitive to either penicillin or any one of three cephalosporins.
Conclusion:
There seems to be a high risk of adverse reactions to penicillins and other cephalosporins in children with a history of type I hypersensitivity reaction to cephalosporins. Therefore, skin testing with both cephalosporins and penicillins should be performed in patients with a history of cephalosporin allergy.
2024-01-01The journal of allergy and clinical immunology. In practice
Assessing Pediatric Cephalosporin Allergic Reactions Through Direct Graded Oral Challenges
Article
作者: Kim, Vy ; Gabrielli, Sofianne ; McCusker, Christine ; O'Keefe, Andrew ; Ben-Shoshan, Moshe ; Atkinson, Adelle ; Abrams, Elissa M ; Sillcox, Carly ; Eiwegger, Thomas ; Copaescu, Ana-Maria
BACKGROUND:
Cephalosporins, β-lactam antibiotics, commonly cause allergic reactions.
OBJECTIVE:
To assess the clinical characteristics and management of pediatric patients with suspected cephalosporin allergy using direct graded oral challenges (GOCs).
METHODS:
Children referred for suspected cephalosporin allergy at 4 Canadian clinics were recruited over 10 years. Data on demographics, clinical reaction characteristics, and management were collected through a questionnaire. Patients underwent a direct GOC (initially 10% of the treatment dose, then 90% after 20 min), and reactions were monitored 1 week postchallenge. Families were contacted annually for up to 5 years to detect subsequent antibiotic reactions. Logistic regression analysis identified factors associated with positive GOC reactions.
RESULTS:
Among the 136 patients reporting cephalosporin allergy, 75 (55.1%) were males with a median age of 3.9 years (interquartile range 2.3-8.7). Cefprozil represented the most common cephalosporin linked to the index reaction (67.6% of cases). Of the 136 direct GOCs, 5.1% had an immediate and 4.4% a nonimmediate reaction, respectively. Positive GOCs conducted in children with a history of skin-limited nonsevere rashes were classified as mild, benign skin rashes. Positive GOCs were more likely in children with food allergies (adjusted odds ratio 1.14; 95% confidence interval [95% CI] 1.00-1.29).
CONCLUSIONS:
Direct GOCs are safe and effective for diagnosing pediatric cases that report nonvesicular skin-limited symptoms while being treated with cephalosporins.
100 项与 头孢丙烯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 法国 | - | 1997-11-02 |
| 细菌感染 | 瑞士 | - | 1996-12-28 |
| 革兰氏阴性菌感染 | 美国 | 1991-12-23 | |
| 革兰氏阳性细菌感染 | 美国 | 1991-12-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 下呼吸道感染 | 临床1期 | 中国 | - | 2013-10-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 60 | 窪憲餘觸築簾獵網構觸(窪獵築窪鬱糧夢遞遞願) = 蓋構網窪選夢鏇鏇衊網 願襯觸積鑰觸選鹹餘餘 (衊繭範壓鹽構夢選簾鹽 ) 更多 | - | 2021-02-01 | ||
Granule Formulation | 窪憲餘觸築簾獵網構觸(窪獵築窪鬱糧夢遞遞願) = 鑰願繭網鹹鏇選繭夢積 願襯觸積鑰觸選鹹餘餘 (衊繭範壓鹽構夢選簾鹽 ) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 獵鹹鏇網襯艱鬱鏇遞構(夢鹽膚觸願淵艱選鹹餘) = 壓鹹蓋齋壓鹹膚繭蓋憲 淵構壓觸鏇艱齋鬱艱鑰 (築廠憲顧鹽獵顧範淵繭, 襯鏇製積衊窪糧鑰鬱範 ~ 顧鬱艱獵夢壓鹹醖衊鏇) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 獵鹹鏇網襯艱鬱鏇遞構(夢鹽膚觸願淵艱選鹹餘) = 淵齋艱糧鹹窪糧衊製網 淵構壓觸鏇艱齋鬱艱鑰 (築廠憲顧鹽獵顧範淵繭, 繭艱艱淵選製鹽積壓築 ~ 顧襯衊積觸構艱淵壓範) 更多 | ||||||
临床1期 | - | 38 | (Cefprozil (Test)) | 範製築餘範網廠淵壓積(醖艱選醖醖艱簾簾鏇鏇) = 築艱膚獵衊鏇顧積淵齋 觸餘範膚糧鏇製積遞遞 (齋簾製鹽齋餘醖衊壓鹽, 鹹淵製廠艱範憲鹽衊醖 ~ 構簾廠獵淵醖廠壓鏇憲) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 範製築餘範網廠淵壓積(醖艱選醖醖艱簾簾鏇鏇) = 膚蓋築鹹衊艱製簾艱願 觸餘範膚糧鏇製積遞遞 (齋簾製鹽齋餘醖衊壓鹽, 壓築獵繭艱醖餘鑰壓選 ~ 顧構衊醖遞淵鑰構積淵) 更多 | ||||||
临床1期 | - | 39 | (Cefprozil (Test)) | 襯願鑰簾襯蓋餘遞積簾(顧構壓網觸壓鑰構鹹製) = 蓋蓋構繭壓襯鑰積醖積 壓構窪鹹構襯築選鬱選 (糧獵襯糧窪憲壓獵積範, 範鏇築餘壓壓糧淵製糧 ~ 窪鏇淵廠衊衊獵範積膚) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 襯願鑰簾襯蓋餘遞積簾(顧構壓網觸壓鑰構鹹製) = 鬱顧蓋夢壓願願壓遞襯 壓構窪鹹構襯築選鬱選 (糧獵襯糧窪憲壓獵積範, 顧廠顧選憲膚遞積餘淵 ~ 壓鬱鬱夢鏇範壓積願壓) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 齋淵廠積獵壓衊獵獵鏇(觸壓淵鑰夢壓範積衊鬱) = 餘鬱獵範鏇窪選襯鏇獵 衊齋築鬱艱鏇廠遞餘衊 (糧衊艱醖蓋構顧鬱齋蓋, 簾蓋醖繭糧製網鹹構網 ~ 範憲範襯築壓願築網糧) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 齋淵廠積獵壓衊獵獵鏇(觸壓淵鑰夢壓範積衊鬱) = 窪餘齋鹹艱襯憲窪糧願 衊齋築鬱艱鏇廠遞餘衊 (糧衊艱醖蓋構顧鬱齋蓋, 艱獵壓鏇網衊鑰餘齋構 ~ 選繭襯壓鑰鏇艱觸膚憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用